Strategic Framework for the South-East Asia Regional Vaccine Action Plan 2022−2030 as aligned with the global Immunization Agenda 2030

Abstract

In August 2020, the Seventy-third World Health Assembly adopted Decision WHA73(‎9)‎endorsing the new global vision and overarching strategy for vaccines and immunization: the global Immunization Agenda 2030 (‎IA2030)‎. In May 2021, the Seventy-fourth World Health Assembly noted the IA2030 Framework for Action, which outlined the route by which IA2030 would be operationalized at the country and regional levels.During 2020, a Strategic Framework for the South-East Asia Regional Vaccine Action Plan 2022−2030 was developed, by adapting the global IA2030 strategy to the regional context. This Regional Strategic Framework was presented to the South-East Asia Regional Immunization Technical Advisory Group (‎SEAR ITAG)‎ in 2020. The Framework has now been revised (‎refer to the Information Document SEA/RC74/8, Inf. Doc. 1)‎ to include guidance on coordinated planning, monitoring and evaluation, ownership and accountability, and communications and advocacy provided in the IA2030 Framework for Action that was endorsed by the Seventy-fourth World Health Assembly.The Strategic Framework for the South-East Asia Regional Vaccine Action Plan2022−2030 outlines the approach that will be taken to ensure effective implementation of the strategy through a South-East Asia Regional Vaccine Implementation Plan that will initially cover the period 2022–2026. The Regional Vaccine Implementation Plan is being developed in collaboration with Member States and partners to capture details of the planning and reporting mechanisms, including the regional monitoring and evaluation framework, which will incorporate globally mandated indicators as well as a core set of region-specific country-level indicators. The Strategic Framework, in conjunction with the Regional Vaccine ImplementationPlan, is intended to provide a seamless transition from the current Regional Vaccine ActionPlan 2016–2020 (‎extended to 2021)‎ by maintaining a focus on key regional priorities while introducing new elements that reflect emerging challenges and opportunities.The Attached working paper and the Strategic Framework for the South-East AsiaRegional Vaccine Action Plan 2022−2030, as aligned with the global IA2030, was submitted to the High-Level Preparatory Meeting for its review and recommendations. The HLP Meeting reviewed the paper and made the following recommendations.Actions by Member States(‎1)‎ Deliberate on the Strategic Framework for the South-East Asia Regional Vaccine Action Plan 2022−2030 during the Seventy-fourth Session of the Regional Committee.(‎2)‎ Collaborate with WHO and partners in developing the South-East Asia Regional Vaccine Implementation Plan 2022−2026, under the umbrella of the Strategic Framework for the South-East Asia Regional Vaccine Action Plan 2022−2030 and adapt this during the development of national plans for immunization.(‎3)‎ Initiate urgent actions to improve process of the restoration of immunization services and vaccine-preventable disease surveillance from the impact of the COVID-19 pandemic, by applying the principles outlined in the Strategic Framework 2022−2030 to improve immunization coverage and overall vaccine-preventable disease control.Actions by WHO(‎1)‎ Support the finalization of the South-East Asia Regional Vaccine Implementation Plan 2022−2026, under the umbrella of the Strategic Framework for the South-East Asia Regional Vaccine Action Plan 2022−2030, incorporating the guidance of Member States on improving coverage and equity, integration of immunization with primary health care while rolling out and scaling up COVID 19 vaccine deployment in the Region.(‎2)‎ Strengthen existing partnerships to support Members States to adapt and implement the Strategic Framework for the South-East Asia Regional Vaccine Action Plan 2022−2030 and its Implementation Plan 2022−2026 through the national multiyear plans for immunizationThe Working Paper and the HLP Meeting recommendations are submitted to the Seventy-fourth Session of the WHO Regional Committee for South-East Asia for its consideration and endorsement.